Evidence map›Paper›PMID 40458728›Full record

ArticleFrontiers in oncology2025

Focal adhesion kinase promotes ribosome biogenesis to drive advanced thyroid cancer cell growth and survival.

Meghan D Kellett, Vibha Sharma, Madeline E Sherlock, Umarani Pugazhenthi, Madison M Rose, Molishree U Joshi, Monika Dzieciatkowska, Vu Nguyen, Philip Reigan, Kirk C Hansen and 2 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Meghan D KellettDivision of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado, Aurora, CO, United States.
Vibha SharmaDivision of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado, Aurora, CO, United States.
Madeline E SherlockDepartment of Biochemistry and Molecular Genetics, University of Colorado, Aurora, CO, United States.
Umarani PugazhenthiDivision of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado, Aurora, CO, United States.
Madison M RoseDivision of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado, Aurora, CO, United States.
Molishree U JoshiDepartment of Pharmacology, University of Colorado, Aurora, CO, United States.
Monika DzieciatkowskaDivision of Structural Biology and Biophysics, Department of Medicine, University of Colorado, Aurora, CO, United States.
Vu NguyenDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, United States.
Philip ReiganDepartment of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, United States.
Kirk C HansenDivision of Structural Biology and Biophysics, Department of Medicine, University of Colorado, Aurora, CO, United States.
Jeffrey S KieftDepartment of Biochemistry and Molecular Genetics, University of Colorado, Aurora, CO, United States.
Rebecca E SchweppeDivision of Endocrinology, Metabolism, and Diabetes, Department of Medicine, University of Colorado, Aurora, CO, United States.

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.P50CA261605 · NCI · UNIVERSITY OF COLORADO DENVER · PI JIMENO, ANTONIO, WANG, XIAO-JING · 2021 to 2025
$10.1M
Training Program in Cancer BiologyT32CA190216 · NCI · UNIVERSITY OF COLORADO DENVER · PI Craig T. Jordan · 2016 to 2026
$3.5M
Targeting FAK and Src in thyroid cancerR01CA222299 · NCI · UNIVERSITY OF COLORADO DENVER · PI SCHWEPPE, REBECCA ELIZABETH · 2018 to 2022
$2.6M
Targeting Focal Adhesion Kinase in Thyroid CancerR01CA164193 · NCI · UNIVERSITY OF COLORADO DENVER · PI SCHWEPPE, REBECCA ELIZABETH · 2012 to 2016
$1.6M
NCI NIH HHS P30 CA046934NCI NIH HHS P50 CA261605NCI NIH HHS R01 CA164193NCI NIH HHS R01 CA222299NCI NIH HHS T32 CA190216
6 · The paper itself

Abstract

Introduction: Advanced thyroid cancer, including papillary (PTC) and anaplastic thyroid cancer (ATC), are the leading causes of endocrine cancer deaths. Thus, there is a critical need to identify novel therapeutic targets to improve standard of care. Focal Adhesion Kinase (FAK) is overexpressed and phosphorylated in thyroid cancer and drives thyroid cancer growth, invasion, and metastasis. FAK is a nonreceptor tyrosine kinase that is autophosphorylated at tyrosine 397 (Y397) in response to integrin or growth factor receptor signaling, resulting in the recruitment of SRC proto-oncogene and downstream signaling pathways. FAK is predominately localized at the plasma membrane but has recently been shown to accumulate in the nucleus as well as the nucleolus to drive tumor growth. The nucleolus is a membraneless subnuclear organelle that is involved in ribosomal biogenesis through the transcription, processing, and assembly of ribosomal RNA (rRNA). The role of FAK in ribosome biogenesis is currently unknown. Methods: Nuclear/nucleolar FAK localization and function were studied using genetic and pharmacological approaches. High resolution microscopy was used to study the subcellular localization of FAK. Functional and biochemical assays including transformation and clonogenic assays, polysome profiling, and nascent protein synthesis assays were utilized to assess cell growth and survival. Protein-protein interactions of FAK were determined using a proximity dependent biotinylation (BioID) proteomics approach. Results: We have found that pY397 FAK accumulates in the nucleolus of advanced thyroid cancer cells and that autophosphorylation of FAK at pY397 and FAK kinase activity are important for nucleolar accumulation of FAK. Furthermore, knockdown of nucleophosmin 1 (NPM1), an important structural component of the nucleolus, reduced pY397 FAK nucleolar accumulation. Functionally, we showed that nuclear FAK and FAK kinase activity are necessary for anchorage independent growth. We demonstrated that targeted degradation of FAK results in decreased protein synthesis with a specific decrease in the 60S ribosomal subunit. Using a BioID proteomics approach, we showed that autophosphorylated FAK interacts with a network of nucleolar proteins including nucleolar protein 56 (NOP56) which is a core small ribonucleoprotein (snoRNP) important for 60S ribosome biogenesis. Finally, we found that pY397 FAK co-localizes with NOP56 and that knockdown of NOP56 phenocopies FAK depletion. Conclusions: Overall, these findings highlight a novel function for FAK in promoting ribosome biogenesis and suggest that nucleolar FAK represents a promising therapeutic target.

Indexed as

focal adhesion kinaseNOP56nucleolusribosomal biogenesisthyroid cancer

Identifiers

PMID40458728
PMCPMC12127332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.